Detalhe da pesquisa
1.
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment.
J Clin Pharmacol
; 63(6): 732-741, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36786053
2.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Lancet Gastroenterol Hepatol
; 8(9): 790-802, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37442152